Raphael Pharmaceutical (RAPH) Net Equity Issued and Repurchased (2022 - 2025)
Raphael Pharmaceutical (RAPH) posted Net Equity Issued and Repurchased of $3000.0 for Q4 2025, down 98.75% sequentially from $240000.0 in Q1 2025.
Raphael Pharmaceutical (RAPH) Net Equity Issued and Repurchased (2022 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $3000.0 in Q4 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $243000.0 (down 13.21% YoY) and the FY2025 annual result came in at $243000.0, down 13.21% from the prior year.
- Net Equity Issued and Repurchased eased to $3000.0 in Q4 2025 per RAPH's latest filing, from $240000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $812000.0 in Q3 2023 and troughed at $3000.0 in Q4 2025.
- A 4-year average of $209428.6 and a median of $112000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2023 and 2025: Net Equity Issued and Repurchased surged 625.0% in 2023, then soared 33.33% in 2025.
- Over 4 years, Net Equity Issued and Repurchased stood at $112000.0 in 2022, then slumped by 83.04% to $19000.0 in 2023, then surged by 426.32% to $100000.0 in 2024, then tumbled by 97.0% to $3000.0 in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $3000.0, $240000.0, and $100000.0 for Q4 2025, Q1 2025, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | 812,000.00 |
| Sep 30, 2023 | 812,000.00 |
| Sep 30, 2022 | 112,000.00 |
| Sep 30, 2022 | 112,000.00 |